Study of the metabolomic relationship between lung cancer and chronic obstructive pulmonary disease based on direct infusion mass spectrometry

被引:19
|
作者
Callejon-Leblic, B. [1 ]
Pereira-Vega, A. [2 ]
Vazquez-Gandullo, E. [2 ]
Sanchez-Ramos, J. L. [3 ]
Gomez-Ariza, J. L. [1 ]
Garcia-Barrera, T. [1 ]
机构
[1] Univ Huelva, Fac Expt Sci, Res Ctr Hlth & Environm RENSMA, Dept Chem, Campus El Carmen, Huelva 21007, Spain
[2] Juan Ramon Jimenez Hosp, Pneumonol Area, Huelva, Spain
[3] Univ Huelva, Nursing Dept, Huelva, Spain
关键词
Metabolomic fingerprinting; Lung cancer; Chronic obstructive pulmonary disease; Serum; Direct infusion; Mass spectrometry; SERUM; BIOMARKERS; DISCRIMINATION; PROGRESSION; PROFILES; MARKERS; PLASMA; URINE;
D O I
10.1016/j.biochi.2018.11.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The high prevalence of lung cancer (LC) has triggered the search of biomarkers for early diagnosis of this disease. For this purpose the study of metabolic changes related to the development of lung cancer could provide interesting information about its early diagnosis. In this sense, chronic obstructive pulmonary disease (COPD), a disease associated with tumor development, is a comorbidity that increases the risk of onset and progression of lung neoplasia and has also to be considered in the study of pathology related to lung cancer. This work develop a metabolomic approach based on direct infusion mass spectrometry using a hybrid triple quadrupole-time of flight mass spectrometer (DI-ESI-QqQ-TOF-MS) in order to identify altered metabolites from serum of LC and COPD patients and evaluate its relationship and implication in the progression of LC. This methodology has been applied to 30 serum samples from LC, 30 healthy patients used as controls (HC) and 30 serum samples from COPD to found altered metabolites from both LC and COPD diseases. In addition, some metabolic differences and similarities were found in Pulmonary Emphysema and Chronic Bronchitis patients. On the other hand, altered metabolites were studied in different stages of LC (II, III and IV) to evaluate the perturbation of them throughout the progression of disease. The sample treatment consisted of the extraction of polar and non-polar metabolites from serum that was later infused into the mass spectrometer using an electrospray ionization source in positive and negative mode. Partial least squares discriminant analysis (PLS-DA) allowed a classification between LC, HC and COPD groups in all acquisition modes. A total of 35 altered and common metabolites between LC and COPD, including amino acids, fatty acids, lysophospholipids, phospholipids and triacylglycerides were identified, being alanine, aspartate and glutamate metabolism the most altered. Finally, ROC curves were applied to the dataset and metabolites with ADC value higher than 0.70 were considered as relevant in the progression of LC. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:111 / 122
页数:12
相关论文
共 50 条
  • [21] Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease
    Deja, Stanislaw
    Porebska, Irena
    Kowal, Aneta
    Zabek, Adam
    Barg, Wojciech
    Pawelczyk, Konrad
    Stanimirova, Ivana
    Daszykowski, Michal
    Korzeniewska, Anna
    Jankowska, Renata
    Mlynarz, Piotr
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, 100 : 369 - 380
  • [22] Severity of Chronic Obstructive Pulmonary Disease and Its Relationship to Lung Cancer Prognosis after Surgical Resection
    Sekine, Yasuo
    Suzuki, Hidemi
    Yamada, Yoshito
    Koh, Eitetsu
    Yoshino, Ichiro
    THORACIC AND CARDIOVASCULAR SURGEON, 2013, 61 (02) : 124 - 130
  • [23] Relationship between incidence of chronic obstructive pulmonary disease and lung cancer as comorbidity in primary health care in two Belgrade communities
    Vasiljevic, Sladjana
    Petrovic, Marina
    Cvetkovic, Aleksandra
    Mikic, Darko
    Paunovic, Vesna
    JOURNAL OF BUON, 2019, 24 (03): : 963 - 966
  • [24] Chronic Obstructive Pulmonary Disease Clinical Implications for Patients With Lung Cancer
    Newsome, Brandi R.
    McDonnell, Karen
    Hucks, Jennifer
    Estrada, Robin Dawson
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2018, 22 (02) : 184 - 192
  • [25] Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective
    Dai, Jie
    Yang, Ping
    Cox, Angela
    Jiang, Gening
    ONCOTARGET, 2017, 8 (11) : 18513 - 18524
  • [26] LUNG CANCER - A COMORBIDITY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Roca, M.
    Roca, Iulia-Cristina
    Mihaescu, T.
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2012, 116 (04): : 1055 - 1062
  • [27] Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry
    Gonzalez-Dominguez, R.
    Garcia-Barrera, T.
    Gomez-Ariza, J. L.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, 98 : 321 - 326
  • [28] Pulmonary Tuberculosis and the Incidence of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease
    Park, Hye Yun
    Kang, Danbee
    Shin, Sun Hye
    Choi, Hayoung
    Jang, Seung Hun
    Lee, Chang-Hoon
    Kim, Hojoong
    Kwon, O. Jung
    Rhee, Chin Kook
    Cho, Juhee
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2022, 19 (04) : 640 - 648
  • [29] There is no relationship between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome: A population study
    Bednarek, M
    Plywaczewski, R
    Jonczak, L
    Zielinski, J
    RESPIRATION, 2005, 72 (02) : 142 - 149
  • [30] Chronic obstructive pulmonary disease and interstitial lung disease in patients with lung cancer
    Mizuno, Satoko
    Takiguchi, Yuichi
    Fujikawa, Ayako
    Motoori, Ken
    Tada, Yuji
    Kurosu, Katsushi
    Sekine, Yasuo
    Yanagawa, Noriyuki
    Hiroshima, Kenzo
    Muraoka, Katsumi
    Mitsushima, Toru
    Niki, Noboru
    Tanabe, Nobuhiro
    Tatsumi, Koichiro
    Kuriyama, Takayuki
    RESPIROLOGY, 2009, 14 (03) : 377 - 383